|
Diaz-Flores E, Comeaux EQ, Kim KL, Melnik E, Beckman K, Davis KL, Wu K, Akutagawa J, Bridges O, Marino R, Wohlfeil M, Braun BS, Mullighan CG, Loh ML. “Bcl-2 Is a Therapeutic Target for Hypodiploid
B-Lineage Acute Lymphoblastic Leukemia.” Cancer Res. 2019 May 1;79(9):2339-2351.
Stieglitz E, Mazor T, Olshen AB, Geng H, Gelston LC, Akutagawa J, Lipka DB, Plass C, Flotho C, Chehab FF, Braun BS, Costello JF, Loh ML. (2017). Genome-wide DNA methylation is predictive of outcome in
juvenile myelomonocytic leukemia. Nature Communications, 8, 2127.
Akutagawa J*, Huang TQ*, Epstein I, Chang T, Quirindongo-Crespo M, Cottonham CL, Dail M, Slusher BS, Friedman LS, Sampath D, Braun BS. (2016). Targeting the PI3K/Akt pathway in murine MDS/MPN driven by
hyperactive Ras. Leukemia, 30(February), 1–9.
Stieglitz E, Troup CB, Gelston LC, Haliburton J, Chow ED, Yu KB, Akutagawa J, Taylor-Weiner AN, Liu YL, Wang YD, Beckman K, Emanuel PD, Braun BS, Abate A, Gerbing RB, Alonzo TA, Loh ML. (2015).
Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia. Blood, 125(3), 516–524.
Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K. (2013). PLC-γ and PI3K
link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras. Science Signaling, 6(304), ra105.
Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K. (2013). Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. Journal of
Clinical Investigation, 123(1), 335–339.
Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS. (2011). A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med, 3(76), 76ra27.
Stephan JP, Chan P, Lee C, Nelson C, Elliott J M, Bechtel C, Raab H, Xie D, Akutagawa J, Baudys J, Saad O, Prabhu S, Wong WL, Vandlen R, Jacobson F, Ebens A. (2008). Anti-CD22-MCC-DM1 and MC-MMAF
conjugates: Impact of assay format on pharmacokinetic parameters determination. Bioconjugate Chemistry, 19(8), 1673–1683.
[top]
|